HiberCell のニュースと活動
存在感
本社所在地：アメリカ合衆国（米国）
HiberCellはGenuity Science,STA Pharmaceutical,WuXi AppTecを含む7の子会社があります。
彼らはにいます：
役員
101人の主要幹部と一緒に組織図を見る
HiberCellでもっとも検索された略歴
- Steven Gillis, Chairman and Acting Chief Executive Officer
- Cindy Jacobs, Director
- Jim Sullivan, Director
アラートを作成
HiberCell のエグゼクティブの異動をフォローします。
バイオテクノロジー
HiberCellはLonza (スイス連邦),Vertex Pharmaceuticals (アメリカ合衆国（米国）),Eurofins (ルクセンブルグ大公国)を含む2,428の競合企業を有します。
Popular M&A news in バイオテクノロジー
- Eli Lilly has announced the acquisition of AtaiBeckley (2026年7月17日に公開).
- ％2$sは％1 $ sを取得しました (2026年7月17日に公開).
- Clearside Biomedical has gone out of its bankruptcy protection (2026年7月15日に公開).
バイオテクノロジー業界でのその他のコンタクトの提案
ニュース
％sによる最新のプレスリリース
- HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 When Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccRCC) at the Upcoming 2026 ASCO Annual Meeting - HiberCell
- HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
- AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound - HiberCell
- HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCC - HiberCell
- HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML) - HiberCell
- HiberCell's Board of Directors Appoints Steven Gillis, Ph.D., the Company's Current Chairman of the Board, as Chairman and Acting CEO - HiberCell
- Jonathan Lanfear Steps Down from Role as President and CEO. HiberCell's Board of Directors Appoints Steven Gillis, Ph.D., the Company's Current Chairman of the Board, as Chairman and Acting CEO. - HiberCell
- HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC - HiberCell
- HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC) - HiberCell
- HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in Combinations - HiberCell
- View more press releases Close
％sについてのソーシャルメディア
- HiberCell についてのウィキペディア,Google News & Yahoo Financeの記事
- HiberCell についてのLinkedIn,ツイッター & YouTubeの記事
